#Norway #Oslo #FDA Breakthrough #neurosurgery #SonoClear System

SonoClear AS Advances Clinical Trials for Innovative System

SonoClear AS, based in Oslo, has announced a major milestone in its efforts to improve neurosurgical procedures with the SonoClear System. Today, they confirmed that the final clinical procedure has been completed in their extensive study focusing on intracranial ultrasound applications tailored for patients battling neurological tumors. This marks a significant step towards enhancing surgical outcomes and patient care in neurosurgery.

CEO Peter Balmforth expressed his satisfaction with the progress, stating, "Having achieved this critical milestone, we are finalizing our data analysis and preparing for the marketing clearance submission in the United States. We owe thanks to the patients, investigators, and clinical teams who have participated in this study."

The SonoClear System

The SonoClear System is designed with an innovative acoustic coupling fluid aimed at advancing intraoperative imaging during neurosurgery. Traditional irrigation fluids often lead to acoustic artifacts that can obscure essential tumor remnants during surgical procedures, complicating the task of achieving maximum resection. Prof. Geirmund Unsgård, Chief Medical Officer at SonoClear, shared insights into the system's capabilities, stating, "The SonoClear System's tissue-mimicking properties were engineered specifically to address these challenges, offering clearer imaging during critical interventions."

The study, led by Prof. Dr. med. Jan Coburger from Ulm University Hospital, prioritizes patient safety in routine intraoperative ultrasound use while comparing the performance of the SonoClear System against standard irrigation fluids. Completing the enrollment phase is pivotal to understanding the broader clinical implications and value of the system.

Breakthrough Device Designation

Back in July 2025, the U.S. FDA recognized the SonoClear System as a Breakthrough Device. This designation not only underscores the potential impact of the device on medical practice but also accelerates the pathway to market availability, pending FDA clearance. SonoClear AS aims to submit a 510(k) application to the FDA in the latter half of 2026, marking a critical milestone for U.S. market entry.

Prof. Dr. Constantin Roder, a participating neurosurgeon from Universitätsklinikum Tübingen (University Hospital Tübingen), noted, "Our experience using the SonoClear System in multiple cases showcased its seamless integration into our operating room workflow. If our observations reflect the overall study results, SonoClear could greatly improve the quality of intraoperative imaging toward the end of the tumor resection process."

Addressing Clinical Needs

The demand for precise, real-time imaging in neurosurgery is paramount. Accurately distinguishing tumor boundaries from healthy brain tissue can significantly influence patient outcomes. While intraoperative ultrasound is frequently utilized in these scenarios, the accuracy of the imaging is frequently compromised by conventional irrigation fluids like saline, which create disruptive acoustic artifacts. A refined coupling fluid could not only enhance surgical precision but also potentially lead to improved survival rates, delayed tumor recurrence, and lowered healthcare costs by reducing the need for repeat surgeries.

About SonoClear AS

SonoClear AS emerged from the Ultrasound and Image-Guided Therapy Centre in Trondheim, Norway, with the mission to elevate diagnostic precision in ultrasound-guided interventions. The enterprise is backed by prominent shareholders, including SINTEF Venture IV, Sarsia, CoFounder, and Sparebank 1 SMN, alongside various family offices and private investors. For further insights into their innovative solutions, visit www.sonoclear.no.